Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience

Wagner K, Müller T, Vitali F, Fischer S, Haberkamp S, Rouse-Merkel R, Atreya R, Neurath M, Zundler S (2024)

Publication Language: English

Publication Type: Journal article

Publication year: 2024

Journal

Therapeutic Advances in Gastroenterology SAGE Publications

Book Volume: 17

DOI: 10.1177/17562848241284051

Abstract

Background: There is an increasing diversification in the treatment landscape for inflammatory bowel diseases (IBD) leading to therapeutic challenges that can only incompletely be covered by prospective randomized double-blind trials. Real-world observations are therefore an important tool to provide insights into therapeutic strategies. Objectives: To describe the real-world treatment algorithms in an IBD referral centre. Design: Single-centre retrospective cohort study. Methods: We retrospectively analysed prospectively collected data on treatment sequences and outcomes from 502 patients with Crohn’s disease (CD) and ulcerative colitis (UC) treated with infliximab, adalimumab, vedolizumab or ustekinumab at a large German tertiary referral centre. Results: Treatment decisions correlated to baseline patient characteristics. Over time, infliximab continued to be the preferred first-line option in CD and UC, although ustekinumab and vedolizumab, respectively, became increasingly important choices. Remission rates decreased with the advancement of therapy lines. Conclusion: We provide insights into the evolution of tertiary centre real-world treatment sequences that might – together with other observations – help to guide the selection of therapies in IBD. Our data also strongly underscore the unmet need for biomarkers supporting treatment decisions. Trial registration: None.

Authors with CRIS profile

Kim Wagner Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Tanja Müller Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Francesco Vitali Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Sarah Fischer Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Sophie Haberkamp Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen Markus Neurath Lehrstuhl für Innere Medizin I (Medizin 1) Sebastian Zundler Professur für Immunzellmigration TT (Else Kröner Clinican Scientist-Professur)

How to cite

APA:

Wagner, K., Müller, T., Vitali, F., Fischer, S., Haberkamp, S., Rouse-Merkel, R.,... Zundler, S. (2024). Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience. Therapeutic Advances in Gastroenterology, 17. https://doi.org/10.1177/17562848241284051

MLA:

Wagner, Kim, et al. "Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience." Therapeutic Advances in Gastroenterology 17 (2024).

BibTeX: Download